Colchicine derivative containing histone deacetylase inhibitory activity, preparation method and application thereof

A technology of sirtuin and colchicine, which is applied in the field of new colchicine derivatives, can solve the problems of complex administration methods, single target, and inconvenient clinical research, and achieve good anti-tumor activity

Inactive Publication Date: 2014-02-05
EAST CHINA NORMAL UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The former has a large number of clinical application examples, but it often brings inconvenience to clinical research due to factors such as drug distribution, different half-lives, and complex administration methods; while the latter can overcome the above-mentioned defects while maintaining synergy, Therefore, it has become an important branch of pharmaceutical chemists in the development of new anti-tumor drugs.
Due to blocking multiple pathways of tumor cell survival, such small molecule drugs can overcome the shortcomings of traditional drugs that are prone to drug resistance
For example, the first-generation tyrosine kinase inhibitor imatinib has a single target, mainly inhibiting the tyrosine kinase Bcr-Abl
Patients tend to develop drug resistance after taking imatinib for a period of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Colchicine derivative containing histone deacetylase inhibitory activity, preparation method and application thereof
  • Colchicine derivative containing histone deacetylase inhibitory activity, preparation method and application thereof
  • Colchicine derivative containing histone deacetylase inhibitory activity, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] 1.1 Preparation of compound 3

[0033] Dissolve 900 mg of monomethyl terephthalate in 10 mL of toluene, add 2.1 mL of thionyl chloride dropwise at room temperature, then raise the temperature to 60-70°C for 2 hours, remove the solvent and excess thionyl chloride under reduced pressure to obtain a colorless liquid . The liquid was dissolved in 5 mL of dichloromethane, and added dropwise to a dichloromethane solution dissolved with 1.1 mL of triethylamine and 832 mg of tert-butyl 2-aminophenylcarbamate, and reacted at room temperature for 30 minutes to stop the reaction. After extraction with dichloromethane, washing with 1N hydrochloric acid and saturated sodium carbonate, the organic phase was dried and spin-dried. The crude product was crystallized in petroleum ether-ethyl acetate to obtain 1.28 g of a white solid, with a yield of 86.5%. 1 H NMR (400MHz, DMSO) δ9.98(s,1H),8.71(s,1H),8.15–8.03(m,4H),7.55(dd,J=13.6,7.8Hz,2H),7.27–7.08( m,2H), 3.91(s,3H), 1.44(s,9H). ...

Embodiment 2

[0035] 1.2 Preparation of compound 4

[0036] At room temperature, 50 mg of compound 3 and 11 mg of lithium hydroxide monohydrate were dissolved in a mixture of 3 mL of ethanol and 0.27 mL of water. After reacting for 1 hour, 1N hydrochloric acid was added to adjust the pH to weak acidity, and the solvent was removed under reduced pressure. The resulting solid, 53 mg deacetylcolchicine, 43 mg diisopropylethylamine, 44 mg 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluoro Phosphate ester was dissolved in 5mL of dichloromethane, reacted at room temperature for two hours, extracted with dichloromethane, washed with 1N hydrochloric acid, washed with water, and the organic phase was dried, separated by column using dichloromethane-methanol as developing solvent, and 62 mg of light yellow solid was obtained , yield 81.1%. 1 H NMR (400MHz, CDCl 3 )δ9.38(s,1H),7.84–7.67(m,6H),7.63(s,1H),7.41–7.35(m,2H),7.23–7.13(m,3H),6.90(d,J= 10.9Hz,1H),6.58(s,1H),4.97–4.81(m,1H),4.00...

Embodiment 3

[0038] 1.3 Preparation of compound 5

[0039]Compound 4 was dissolved in 20 mL of dichloromethane, 3 mL of trifluoroacetic acid was added, and reacted at room temperature for 3 hours. Add saturated sodium carbonate solution to quench the reaction, extract with dichloromethane, wash the organic phase with water, wash with saturated brine, dry over anhydrous sodium sulfate and distill under reduced pressure. The obtained crude product was slurried with dichloromethane-petroleum ether to obtain 31 mg of white solid with a yield of 69.6%. 1 H NMR (400MHz, CDCl 3 )δ9.32(s,1H),8.50(d,J=6.3Hz,1H),7.78(s,1H),7.70(d,J=8.0Hz,2H),7.51(d,J=7.8Hz, 2H),7.37(d,J=10.8Hz,1H),7.26–7.23(m,1H),7.00(t,J=7.4Hz,1H),6.94(d,J=11.0Hz,1H),6.84– 6.68(m,2H),6.56(s,1H),4.98–4.83(m,1H),4.02(s,3H),3.92(s,3H),3.90(s,3H),3.55(s,3H) ,2.61–2.47(m,1H),2.42–2.25(m,2H),2.21–2.09(m,1H).HPLC:room temperature;t R =9.35min, UV 254 =95.6%;HRMS(ESI):m / z calcd for C 34 h 33 N 3 o 7 Na(M+Na + ):618.2216,found:61...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a colchicine derivative that is shown as general formula I and contains histone deacetylase inhibitory activity, its pharmaceutically acceptable salts, a preparation method and application thereof. In the general formula I, X can be carbonyl, methylene, substituted methylene, ethylidene and substituted ethylidene; Y can be an aromatic ring, a substituted aromatic ring, a heteroaromatic ring and a substituted heteroaromatic ring; and Z can be hydrogen, an aromatic ring, a substituted aromatic ring, a heteroaromatic ring and a substituted heteroaromatic ring. The compounds have good anti-tumor activity, and can be applied by means of oral administration, intravenous injection, intramuscular injection and the like clinically.

Description

technical field [0001] The invention relates to a class of multi-target inhibitors acting on microtubules and histone deacetylases, as well as methods and applications for preparing these compounds. More specifically, it relates to novel colchicine derivatives (I) having the following structures, their preparation methods and the application of these compounds in the antitumor field. [0002] Background technique [0003] Microtubules are a polar cytoskeleton, an important factor in maintaining cell shape, and an important class of anti-tumor targets. Colchicine (1) is a representative compound with antitumor activity that acts on the microtubule colchicine binding site, but its application is limited due to its strong toxicity and side effects. [0004] [0005] Combined drug use and the development of single-molecule multi-target drugs are a direction in the field of anti-tumor drug research. The synergistic effect between different targets can increase drug efficac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C233/80C07C231/12C07C237/40C07D333/20A61K31/381A61K31/167A61P35/00
Inventor 吕伟张儇刘雅倩于秀华罗宇方艳芬章雄文陈奕丁健
Owner EAST CHINA NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap